Robinson Anthony E, McAuliffe William, Phillips Timothy J, Phatouros Constantine C, Singh Tejinder P
Neurological Intervention and Imaging Service of Western Australia (NIISWA) , Perth , Western Australia.
Br J Radiol. 2017 Dec;90(1080):20170472. doi: 10.1259/bjr.20170472. Epub 2017 Oct 26.
Embolization is a treatment option for intractable epistaxis; however, concerns regarding tissue necrosis, stroke and blindness persist in the literature.
A retrospective review of patients from September 2010 to January 2016 treated with embolization for epistaxis was performed. No patient was excluded. Follow-up was 12 months and no patient was lost.
62 embolizations on 59 patients occurred. 21 cases were taking anticoagulants, P2Y12 inhibiting agents or had a systemic coagulopathy. Embolized territories typically involved bilateral distal internal maxillary arteries with unilateral or bilateral facial arteries with polyvinyl alcohol particles. 60 cases had procedural general anaesthesia. There were no major complications. Six died of unrelated causes. Of the surviving 53 patients, excluding the 3 patients with hereditary haemorrhagic telangiectasia, 5 had recurrent epistaxis post-embolization. Four were taking P2Y12 inhibiting and/or anticoagulants, none of which required surgery, prolonged packing or repeat embolization. This group had a propensity to recur compared with cases taking aspirin only or no antiplatelet/anticoagulant (77.8 vs 97.1%, p = 0.04). The fifth underwent repeat embolization after previously only having ipsilateral distal internal maxillary and facial arteries treated.
Embolization for epistaxis is safe and effective. Of those who had recurrent epistaxis post embolization, most were taking P2Y12 inhibition and/or anticoagulation. We prefer bilateral distal internal maxillary artery and unilateral facial artery embolization under general anaesthesia for optimal safety and efficacy. Advances in knowledge: Embolization with this technique seems to facilitate superior outcomes without complications despite the large proportion of patients taking anticoagulating or P2Y12 inhibiting agents.
栓塞术是治疗顽固性鼻出血的一种选择;然而,文献中对组织坏死、中风和失明的担忧依然存在。
对2010年9月至2016年1月接受鼻出血栓塞治疗的患者进行回顾性研究。无患者被排除。随访12个月,无患者失访。
对59例患者进行了62次栓塞。21例患者正在服用抗凝剂、P2Y12抑制剂或患有全身性凝血病。栓塞区域通常涉及双侧上颌内动脉远端以及单侧或双侧面动脉,使用聚乙烯醇颗粒。60例手术采用全身麻醉。无重大并发症。6例死于无关原因。在存活的53例患者中,排除3例遗传性出血性毛细血管扩张症患者,5例栓塞后复发性鼻出血。4例正在服用P2Y12抑制剂和/或抗凝剂,均无需手术、长时间填塞或重复栓塞。与仅服用阿司匹林或未服用抗血小板/抗凝剂的病例相比,该组复发倾向更高(77.8%对97.1%,p = 0.04)。第5例患者先前仅治疗了同侧上颌内动脉远端和面动脉,之后接受了重复栓塞。
鼻出血栓塞术安全有效。栓塞后复发性鼻出血的患者中,大多数正在服用P2Y12抑制剂和/或抗凝剂。为了达到最佳的安全性和疗效,我们更倾向于在全身麻醉下进行双侧上颌内动脉远端和单侧面动脉栓塞。知识进展:尽管大部分患者正在服用抗凝剂或P2Y12抑制剂,但采用这种技术进行栓塞似乎能带来更好的效果且无并发症。